Phase II Study Evaluating the Efficacy, Safety, Tolerability and PK of siG12D-LODER in the Treatment of Patients With Unresectable LAPC When Used in Conjunction With Standard Chemotherapy (Gemcitabine+Nab-Paclitaxel) Versus Chemotherapy Alone
Summary
The purpose of this phase II study is to assess the response rate of siG12D-LODER with chemotherapy treatment (gemcitabine+nab-paclitaxel) in patients with unresectable, locally advanced pancreatic cancer.
For more information about the study, please visit: http://pancan-protact.com/
General Information
NCT#: NCT01676259
Study ID: SLSG12D-P2
Trial Phase: Phase II
Trial Sponsor: Silenseed Ltd.
Therapies Used in This Trial: Nab-paclitaxel, Gemcitabine, siG12D-LODER™